Analyst Bullish as Aegerion (AEGR) Drug Approved with Broad Label
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Boosts Target on Aegerion (AEGR) to $29 Ahead of Juxtapid Commercialization
December 27, 2012 7:21 AM ESTJefferies raised its price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) from $24 to $29 after FDA approval for Juxtapid with details on the company's commercial plan expected on Jan 7-10.
The firm notes the labeled indication is in-line with expectation. The key... More
Aegerion Pharmaceuticals (AEGR) Halted on FDA Approval News
December 24, 2012 7:02 AM ESTAegerion Pharmaceuticals (Nasdaq: AEGR) has been halted on FDA approval news. More... More
Aegerion (AEGR) Receives FDA Approval for JUXTAPID Caps
December 24, 2012 7:01 AM ESTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food & Drug Administration (FDA) has approved JUXTAPID (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non- high-density-lipoprotein cholesterol (non-HDL) in patients with homozygous familial hypercholesterolemia (HoFH).
"We are excited that JUXTAPID will become a new treatment option for patients with HoFH," said Marc Beer, Chief Executive Officer at Aegerion. "The approval of our first product also marks an important... More
